GI
GLUE icon

GAMMA Investing’s Monte Rosa Therapeutics GLUE Stock Holding History

GAMMA Investing’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.2K Buy
2,114
+86
+4% +$1.63K ﹤0.01% 2281
2026
Q1 		$33.4K Buy
2,028
+123
+6% +$2.35K ﹤0.01% 2445
2025
Q4 		$29.9K Buy
+1,905
New +$25.7K ﹤0.01% 2395
2025
Q3 		– Sell
-80
Closed -$361 – 3880
2025
Q2 		$361 Sell
80
-1,148
-93% -$5.12K ﹤0.01% 3676
2025
Q1 		$5.7K Sell
1,228
-4,693
-79% -$28.8K ﹤0.01% 3033
2024
Q4 		$41.1K Buy
5,921
+5,866
+10,665% +$44K ﹤0.01% 1814
2024
Q3 		$292 Buy
55
+3
+6% +$15 ﹤0.01% 3459
2024
Q2 		$194 Hold
52
– – ﹤0.01% 3345
2024
Q1 		$367 Buy
+52
New +$308 ﹤0.01% 3149

Other funds holding GLUE

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
DWM
Dogwood Wealth Management Lenexa, Kansas $253M AUM 19.41% 1-Year Est. Return

GAMMA Investing's GLUE Position: Q2 2026 in Review

GAMMA Investing increased its Monte Rosa Therapeutics (GLUE) stake by 4.2% in Q2 2026, buying an estimated $1.63K and bringing the position to 2,114 shares worth $51.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2281.

GAMMA Investing first reported a position in GLUE in Q1 2024 and has held it in 9 quarters since. 8 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • GAMMA Investing held 2,114 shares of Monte Rosa Therapeutics worth $51.2K as of Q2 2026.
  • GAMMA Investing bought 86 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.63K.
  • Monte Rosa Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2281 holding.
  • GAMMA Investing first reported a position in Monte Rosa Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 8 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.